Phosphodiesterase-5 inhibitors and rosacea : report of 10 casesIOANNIDES, D; LAZARIDOU, E; APALLA, Z et al.British journal of dermatology (1951). 2009, Vol 160, Num 3, pp 719-720, issn 0007-0963, 2 p.Article

Alprostadil for the treatment of impotenceHANCHANALE, Vishwanath; EARDLEY, Ian.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 3, pp 421-428, issn 1465-6566, 8 p.Article

Erectile dysfunction and heart failure : the role of phosphodiesterase type 5 inhibitorsAL-AMERI, H; KLONER, R. A.International journal of impotence research. 2009, Vol 21, Num 3, pp 149-157, issn 0955-9930, 9 p.Article

Is phosphodiesterase type 5 inhibitor use associated with condom breakage? CommentaryCROSBY, R; YARBER, W. L; SANDERS, S. A et al.Sexually transmitted infections. 2009, Vol 85, Num 5, pp 404-406, issn 1368-4973, 3 p.Article

Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitorsDRESSER, M. J; DESAI, D; GIDWANI, S et al.International journal of impotence research. 2006, Vol 18, Num 1, pp 104-110, issn 0955-9930, 7 p.Article

Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors : Focus on «-blocker interactionsKLONER, Robert A.The American journal of cardiology. 2005, Vol 96, Num 12B, pp 42M-46M, issn 0002-9149Conference Paper

Role of Growth Factors in Improved Skin Flap Viability Caused by Phosphodiesterase-5 InhibitorBANDERA, Bradley C; PHAM, Thach; HILL-PRYOR, Crystal et al.The American surgeon. 2010, Vol 76, Num 6, pp 614-617, issn 0003-1348, 4 p.Article

Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction : Phosphodiesterase 5 inhibitors : pharmacology and therapeutic perspectivesAVERSA, Antonio; BRUZZICHES, Roberto; PILI, Marcello et al.Current pharmaceutical design. 2006, Vol 12, Num 27, pp 3467-3484, issn 1381-6128, 18 p.Article

Sex and the heartSCHWARZ, E. R; RODRIGUEZ, J.International journal of impotence research. 2005, Vol 17, pp S4-S6, issn 0955-9930, SUP1Conference Paper

Combined use of phosphodiesterase-5 inhibitors and selective serotonin reuptake inhibitors for temporary ejaculation failure in couple undergoing assisted reproductive technologiesSHAOMING LU; YUERAN ZHAO; JINGMEI HU et al.Fertility and sterility. 2009, Vol 91, Num 5, pp 1806-1808, issn 0015-0282, 3 p.Article

A multifaceted approach to maximize erectile function and vascular healthMELDRUM, David R; GAMBONE, Joseph C; MORRIS, Marge A et al.Fertility and sterility. 2010, Vol 94, Num 7, pp 2514-2520, issn 0015-0282, 7 p.Article

Sudden Hearing Loss From PDE-5 Inhibitors: A Possible Cellular Stress EtiologyMADDOX, Patrick T; SAUNDERS, James; CHANDRASEKHAR, Sujana S et al.The Laryngoscope. 2009, Vol 119, Num 8, pp 1586-1589, issn 0023-852X, 4 p.Conference Paper

Pharmacology of phosphodiesterase-5 inhibitorsCORBIN, J. D; FRANCIS, S. H.International journal of clinical practice (Esher). 2002, Vol 56, Num 6, pp 453-459, issn 1368-5031Article

Isolation and structure elucidation of an interaction product of aminotadalafil found in an illegal health food productHÄBERLI, Adrian; GIRARD, Philippe; LOW, Min-Yong et al.Journal of pharmaceutical and biomedical analysis. 2010, Vol 53, Num 1, pp 24-28, issn 0731-7085, 5 p.Article

Erectile Dysfunction and Cardiovascular Disease : Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both ConditionsNEHRA, Ajay.Mayo Clinic proceedings. 2009, Vol 84, Num 2, pp 139-148, issn 0025-6196, 10 p.Article

Lifestyle and metabolic approaches to maximizing erectile and vascular healthMELDRUM, D. R; GAMBONE, J. C; MORRIS, M. A et al.International journal of impotence research. 2012, Vol 24, Num 2, pp 61-68, issn 0955-9930, 8 p.Article

Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in menSTIRBAN, Alin; TAMLER, Ronald; ANDREI VERESIU, Loan et al.Journal of men's health (Print). 2011, Vol 8, Num 2, pp 109-118, issn 1875-6867, 10 p.Article

How to optimise treatment of erectile dysfunction above and beyond the beneficial effects of a phosphodiesterase type 5 inhibitorGOOREN, Louis.Journal of men's health. 2008, Vol 5, Num 2, pp 163-170, 8 p.Article

Structural elucidation of a PDE-5 inhibitor detected as an adulterant in a health supplementXIAOWEI GE; LOW, Min-Yong; PENG ZOU et al.Journal of pharmaceutical and biomedical analysis. 2008, Vol 48, Num 4, pp 1070-1075, issn 0731-7085, 6 p.Article

Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lambJAILLARD, Sophie; LARRUE, Benoit; DERUELLE, Philippe et al.The Annals of thoracic surgery. 2006, Vol 81, Num 3, pp 935-942, issn 0003-4975, 8 p.Article

Cardiac safety in clinical trials of phosphodiesterase 5 inhibitorsCARSON, Culley C.The American journal of cardiology. 2005, Vol 96, Num 12B, pp 37M-41M, issn 0002-9149Conference Paper

Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?AVERSA, A; FRANCOMANO, D; BRUZZICHES, R et al.International journal of impotence research. 2011, Vol 23, Num 1, pp 17-23, issn 0955-9930, 7 p.Article

Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction : results from the Erectile Dysfunction Observational StudyHATZICHRISTOU, D; HARE, J. M; MARTIN-MORALES, A et al.International journal of clinical practice (Esher). 2007, Vol 61, Num 11, pp 1850-1862, issn 1368-5031, 13 p.Article

Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patientsATTINA, Teresa M; MALATINO, Lorenzo S; MAXWELL, Simon R et al.Journal of hypertension. 2008, Vol 26, Num 3, pp 501-507, issn 0263-6352, 7 p.Article

Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in miceDHIR, Ashish; KULKAMI, S. K.Progress in neuro-psychopharmacology & biological psychiatry. 2007, Vol 31, Num 4, pp 921-925, issn 0278-5846, 5 p.Article